A number of heavy drugs "card lines" were approved, and this year's medical insurance negotiation situation is full of variables

Before the national medical insurance negotiations, potential popular varieties always attract great attention.

On June 29, the State Medical Insurance Bureau announced the "National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog Adjustment Work Plan" in 2022, and announced the official launch of the fifth round of national medical insurance negotiations. According to regulations, the enterprise's declaration must be approved by the listing before June 30 this year.

According to statistics from the Jianzhi Bureau, from July 1, 2021 to June 30, 2022, domestic innovative drugs and new indications approved for listing were added to more than 30 species, mainly cancer drugs, mainly cancer drugs, diabetes, leukemia drugs Secondly, there are 11 Chinese medicine products. These are the highlights of this year's national talks.

A number of new drugs "card points" are approved

The negotiation battle is sent when it is touched

A variety of new drugs "card points" were approved, and the negotiation war was sent immediately

On June 29, the State Drug Administration approved three new drugs to be listed, namely the PD-1/CTLA-4 dual anti-CTLA-4 dual anti-Kadini Midella, Hengrui's prostate drugs, and the Riviluamamine, and Bayer's hypoglycemic drugs Feilitone tablets.

One day later, these three products may miss the medical insurance negotiation declaration this year.

According to data from the State Drug Administration, in the past year, Hengrui Pharmaceuticals have been listed on proline Hengge Ledine, hydroxyticate Dalisi tablets and Revilunamide tablets. The number ranks first in domestic enterprises. According to data disclosed by Hengrui, the cumulative investment in these three medicines has invested 996 million yuan. After entering the medical insurance, these products can quickly spread out the market.

The record in traditional Chinese medicine is also considerable. In the second half of 2021, 11 Chinese medicines including Yiling Pharmaceutical's Yishen Yangxin and Safe Film, Xieyu and Removal Capsule, and Qi Rui Stomato Capsules of Jianmin Pharmaceuticals were listed. About 40%of the total.

Among the newly listed products, there are some complicated varieties of "life", such as Shengnuoki's subsidiary Xunnakin Medicine's 淫 淫 素 soft capsule, which is suitable for the treatment of liver cell carcinoma.

Epimedium is a medicine unique to traditional Chinese medicine and is often used for kidney and aphrodisiac. When Shengnuki developed an AIDS medication based on Epimedium as the main ingredient, it was found that it could also take effect on breast cancer and lung cancer, so there was this anthochexin soft capsule that cured liver cancer. In May 2020, Sheng Nuoki's "core product" of the "core product" of the "core product" 淫 淫 素 soft capsule submitted an IPO on the science and technology board, and has not yet made progress.

In the first half of this year, multinational pharmaceutical companies listed at least 5 anti -cancer drugs in China, including Bayer's oral NTRK inhibitors Larotinib, Incete's bile duct cancer targeting medicine Pemininib, Pfizer's ALK inhibitor work Latini et al.

Data source: National Drug Administration

It is worth mentioning that Larotinib is a "broad -spectrum anti -cancer drug", which has been listed in the United States in 2018. According to data released by Bayer at this year's American Clinical Oncology Society, the objective relief rate of Larotinib the objective relief rate of children's physical tumor patients with NTRK gene fusion is as high as 84%, and non -expected adverse reactions have not occurred.

The enthusiasm for multinational pharmaceutical companies to participate in medical insurance price negotiations is not small, but due to the global price system, it is not willing to reduce prices in China. But often the "soul bargain" scenes are often on multinational pharmaceutical companies.

Celebrit

Who does the directory quota fall?

In 2022, the medical insurance negotiations, the PD-1 war ushered in more variables.

On the one hand, the new competitors entered the game: In the second half of 2021, Kangfang's Patto April Midarity, Fu Hong Hanlin's Sroari Meticuke was listed one after another. Another unique advantage in indications.

On the other hand, the "Four Little Dragons" that continue to work: Cinda's Xindi Mipida, Baiji Shenzhou's Darleyzab, and Junshi Tripley Mippling successively took nasopharyngeal cancer and esophageal pipes. Substation and gastric cancer indications. According to the convention, it is definitely necessary to participate in the "one -day tour" of medical insurance. In addition, several internal PD-1 in the medical insurance have expired this year, and the "renewal" war was at the end.

Another stirring market is Kangfang's "Card Point" approved Kadonilicab. This is the first approved domestically produced dual-resistant, and it is also the world's first PD-1-based dual-anti-developed dual-anti-drug. At the moment when the market has entered the fierceization, Kang Fang came with a "upgraded version" product, and his intention was self -evident.

"Sky Price Medicine" CAR-T is another highlight.

In 2021, Fosun Kate's CAR-T product Akilun Saitor injection passed a formal review, but the sky-high price of 1.2 million yuan was not entered the negotiation link. In March of this year, data disclosed by Fosun showed that as of the end of February this year, there were only a hundred patients using this product.

This year, Fosun Kate has an opponent. At the beginning of September 2021, Yao Ming Junuo's Car-T Riki Olun Saitor injection was approved to be listed at a price of 1.29 million yuan, which was more expensive than Fosun's products. The Jianzhi Bureau noticed that so far, Fosun and Yao Ming Juuo have not issued a notice of price reduction. According to the current pricing of the two products, it may still miss this year's medical insurance negotiations.

Another point is rare disease. In this year's medical insurance catalog adjustment document, the State Medical Insurance Bureau mentioned that it encourages the participation of rare diseases and relaxes its listing period. As long as it is a product listed on June 30 this year, it can be involved.

In 2021, Bo Jian's "700,000 yuan per pin" of the spinal cord muscle atrophy (SMA) drug Nosnina sodium was successfully shortlisted, and the annual fee dropped to less than 100,000 yuan.This year, Roche's oral SMA product Lispoland took the initiative to reduce prices in June and controlled the annual fee within 450,000 yuan.Obviously, Roche went to the medical insurance.This year, if Lichi Panlan can really be shortlisted, the position of the SMA market leader, Bo Jian may not sit so stable.

Writing ｜ Guyue

Edit ｜ Jiang Yun Jia Ting

Operation ｜ Valley

Illustration | Visual China

- END -